Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cancer (NSCLC).

In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat ...

This page includes links to articles highlighting the top lung cancer research published on Cancer Therapy Advisor in 2024.

引言2024 年 11 月份，美国临床肿瘤学会（ASCO）基于最新的循证医学证据及美国食品药品监督管理局（FDA）的药物审批动态，在其官方杂志 Journal of Clinical Oncology 上发布了两则《ASCO ...

Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cancer (NSCLC).

CHICAGO -- Subcutaneous amivantamab (Rybrevant) was non-inferior to IV amivantamab for pre-treated patients with refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC), with the ...

Principal treatment-related toxicities that come from amivantamab administration include skin-related reactions, higher risk of venous thrombolism, and infusion-related reactions. With numerous ...

Further information Decision makers have concluded that this technology will not progress as a potential technology appraisal or a highly specialised technology. This decision follows consideration of ...